Prometheus Biosciences $500 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
We advised the representatives of the several underwriters in connection with the $500 million public offering of 4,545,455 shares of common stock by Prometheus Biosciences Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “RXDX.”
Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The company’s precision medicine platform, Prometheus360, includes one of the world’s largest gastrointestinal bioinformatics databases and sample biobank to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.
The Davis Polk corporate team included partner Deanna L. Kirkpatrick and counsel Hillary A. Coleman. The intellectual property and technology transactions team included partner David R. Bauer and associate Alison T. Chin. The tax team included counsel Alon Gurfinkel and associate Charles Collier. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and London offices.